C.P. Group Innovation

C.P. Group Innovation is the research and development arm of the Charoen Pokphand Group (C.P. Group), a leading global conglomerate based in Thailand with a significant presence in the life sciences sector. The division coordinates the group's innovation strategy, primarily executed through its major subsidiary, Sino Biopharmaceutical Limited, and its various pharmaceutical units like Chia Tai Tianqing. C.P. Group Innovation focuses on developing a broad range of therapeutic products, including innovative biologics, small molecules, and cell therapies, targeting high-unmet-need areas such as oncology, liver disease, and respiratory ailments. By integrating advanced biotechnology with the group's extensive industrial infrastructure, the division aims to drive the commercialization of next-generation healthcare solutions across the Asia-Pacific region and globally. The group maintains a robust pipeline with numerous candidates in late-stage clinical trials and has established strategic partnerships with international pharmaceutical leaders to expand its technological capabilities.